Today’s Wall Street Journal article, “Novo Nordisk to Slash Insulin Prices by Up to 75%” lets us know that come January 2024 Novo will reduce the cost of its popular rapid-acting Novolog by 75% and Novolin and Levemir by 65%. This follows Eli Lilly’s price reduction scheduled for later this year.
So, Sanofi what about you?
Diabetes Stories 
Pingback: Novo Nordisk follows Eli Lilly to decrease insulin costs subsequent 12 months - KaihanSaffron
Pingback: Novo Nordisk follows Eli Lilly to lower insulin prices next year – GenkiWellness.com